Ash Stevens, Inc. (ASI) has received FDA approval of its facility in Riverview, MI to manufacture the API in ARIAD Pharmaceuticals’ drug Iclusig (ponatinib), which was recently approved to treat chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant to prior TKI therapy.
 
“We are very proud to be ARIAD Pharmaceuticals’ outsourcing partner for the development and manufacture of this important API. We have a collaborative and highly productive relationship with ARIAD and we are excited to help provide this innovative therapy to cancer patients,” said Dr. Stephen A. Munk, president and chief executive officer of Ash Stevens, Inc. Ash Stevens to Manufacture API for ARIAD Drug